Does the media favor RAPP or RGNX?

In the previous week, Rapport Therapeutics had 7 more articles in the media than REGENXBIO. MarketBeat recorded 8 mentions for Rapport Therapeutics and 1 mentions for REGENXBIO. Rapport Therapeutics' average media sentiment score of 0.37 beat REGENXBIO's score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, RGNX or ADMA?

ADMA Biologics has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.94 -$193.88M -$5.60 N/A ADMA Biologics $510.17M 3.84 $146.93M $0.68 12.44

Is RGNX or ADMA more profitable?

ADMA Biologics has a net margin of 32.43% compared to REGENXBIO's net margin of -330.23%. ADMA Biologics' return on equity of 39.98% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -330.23% -232.50% -61.02% ADMA Biologics 32.43% 39.98% 28.08%

Does the media prefer RGNX or ADMA?

In the previous week, ADMA Biologics had 39 more articles in the media than REGENXBIO. MarketBeat recorded 40 mentions for ADMA Biologics and 1 mentions for REGENXBIO. ADMA Biologics' average media sentiment score of 0.06 beat REGENXBIO's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 37 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or RGNX?

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Aurinia Pharmaceuticals and 1 mentions for REGENXBIO. Aurinia Pharmaceuticals' average media sentiment score of 1.50 beat REGENXBIO's score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, PGEN or RGNX?

REGENXBIO has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 230.92 -$250.64M -$1.18 N/A REGENXBIO $170.44M 2.94 -$193.88M -$5.60 N/A

Is PGEN or RGNX more profitable?

REGENXBIO has a net margin of -330.23% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% REGENXBIO -330.23% -232.50% -61.02%

Does the media favor PGEN or RGNX?

In the previous week, Precigen had 5 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for Precigen and 1 mentions for REGENXBIO. Precigen's average media sentiment score of 0.58 beat REGENXBIO's score of 0.00 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, URGN or RGNX?

Urogen Pharma has higher earnings, but lower revenue than REGENXBIO. Urogen Pharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 16.97 -$153.49M -$2.75 N/A REGENXBIO $170.44M 2.94 -$193.88M -$5.60 N/A

Is URGN or RGNX more profitable?

Urogen Pharma has a net margin of -94.83% compared to REGENXBIO's net margin of -330.23%. Urogen Pharma's return on equity of 0.00% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Urogen Pharma -94.83% N/A -62.85% REGENXBIO -330.23% -232.50% -61.02%

Does the media prefer URGN or RGNX?

In the previous week, Urogen Pharma had 8 more articles in the media than REGENXBIO. MarketBeat recorded 9 mentions for Urogen Pharma and 1 mentions for REGENXBIO. Urogen Pharma's average media sentiment score of 0.97 beat REGENXBIO's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

REGENXBIO (RGNX) Competitors

$9.69 -0.43 (-4.25%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$9.71 +0.02 (+0.25%)

As of 07/31/2026 07:34 PM Eastern

Compare

RGNX vs. RAPP, ADMA, AUPH, PGEN, and URGN

Should you buy REGENXBIO stock or one of its competitors? MarketBeat compares REGENXBIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with REGENXBIO include Rapport Therapeutics (RAPP), ADMA Biologics (ADMA), Aurinia Pharmaceuticals (AUPH), Precigen (PGEN), and Urogen Pharma (URGN).

How does REGENXBIO compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Rapport Therapeutics had 7 more articles in the media than REGENXBIO. MarketBeat recorded 8 mentions for Rapport Therapeutics and 1 mentions for REGENXBIO. Rapport Therapeutics' average media sentiment score of 0.37 beat REGENXBIO's score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rapport Therapeutics has higher earnings, but lower revenue than REGENXBIO. Rapport Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
REGENXBIO	$170.44M	2.94	-$193.88M	-$5.60	N/A

Rapport Therapeutics presently has a consensus target price of $57.86, indicating a potential upside of 41.18%. REGENXBIO has a consensus target price of $23.82, indicating a potential upside of 145.80%. Given REGENXBIO's higher possible upside, analysts clearly believe REGENXBIO is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

88.1% of REGENXBIO shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rapport Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Rapport Therapeutics' return on equity of -24.78% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
REGENXBIO	-330.23%	-232.50%	-61.02%

Rapport Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Rapport Therapeutics beats REGENXBIO on 10 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to ADMA Biologics?

REGENXBIO (NASDAQ:RGNX) and ADMA Biologics (NASDAQ:ADMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, ADMA Biologics had 39 more articles in the media than REGENXBIO. MarketBeat recorded 40 mentions for ADMA Biologics and 1 mentions for REGENXBIO. ADMA Biologics' average media sentiment score of 0.06 beat REGENXBIO's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	37 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.94	-$193.88M	-$5.60	N/A
ADMA Biologics	$510.17M	3.84	$146.93M	$0.68	12.44

REGENXBIO has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ADMA Biologics has a net margin of 32.43% compared to REGENXBIO's net margin of -330.23%. ADMA Biologics' return on equity of 39.98% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
ADMA Biologics	32.43%	39.98%	28.08%

REGENXBIO presently has a consensus price target of $23.82, indicating a potential upside of 145.80%. ADMA Biologics has a consensus price target of $18.67, indicating a potential upside of 120.65%. Given REGENXBIO's stronger consensus rating and higher probable upside, research analysts clearly believe REGENXBIO is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ADMA Biologics beats REGENXBIO on 10 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Aurinia Pharmaceuticals presently has a consensus target price of $17.33, suggesting a potential upside of 16.49%. REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 145.80%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts plainly believe REGENXBIO is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to REGENXBIO's net margin of -330.23%. Aurinia Pharmaceuticals' return on equity of 26.62% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
REGENXBIO	-330.23%	-232.50%	-61.02%

Aurinia Pharmaceuticals has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	6.76	$287.20M	$2.17	6.86
REGENXBIO	$170.44M	2.94	-$193.88M	-$5.60	N/A

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Aurinia Pharmaceuticals and 1 mentions for REGENXBIO. Aurinia Pharmaceuticals' average media sentiment score of 1.50 beat REGENXBIO's score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Precigen?

Precigen (NASDAQ:PGEN) and REGENXBIO (NASDAQ:RGNX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

REGENXBIO has a net margin of -330.23% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
REGENXBIO	-330.23%	-232.50%	-61.02%

33.5% of Precigen shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 99.36%. REGENXBIO has a consensus price target of $23.82, suggesting a potential upside of 145.80%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts clearly believe REGENXBIO is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, Precigen had 5 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for Precigen and 1 mentions for REGENXBIO. Precigen's average media sentiment score of 0.58 beat REGENXBIO's score of 0.00 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precigen has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, REGENXBIO has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

REGENXBIO has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	230.92	-$250.64M	-$1.18	N/A
REGENXBIO	$170.44M	2.94	-$193.88M	-$5.60	N/A

Summary

Precigen and REGENXBIO tied by winning 8 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Urogen Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

In the previous week, Urogen Pharma had 8 more articles in the media than REGENXBIO. MarketBeat recorded 9 mentions for Urogen Pharma and 1 mentions for REGENXBIO. Urogen Pharma's average media sentiment score of 0.97 beat REGENXBIO's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Urogen Pharma presently has a consensus target price of $41.63, indicating a potential upside of 8.85%. REGENXBIO has a consensus target price of $23.82, indicating a potential upside of 145.80%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Urogen Pharma has a net margin of -94.83% compared to REGENXBIO's net margin of -330.23%. Urogen Pharma's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
REGENXBIO	-330.23%	-232.50%	-61.02%

Urogen Pharma has higher earnings, but lower revenue than REGENXBIO. Urogen Pharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	16.97	-$153.49M	-$2.75	N/A
REGENXBIO	$170.44M	2.94	-$193.88M	-$5.60	N/A

Summary

Urogen Pharma beats REGENXBIO on 11 of the 17 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$500.95M	$3.55B	$7.17B	$12.47B
Dividend Yield	N/A	3.79%	2.60%	9.45%
P/E Ratio	-1.73	7.38	282.25	24.53
Price / Sales	2.94	1,250.89	584.89	90.56
Price / Cash	N/A	98.58	71.23	59.99
Price / Book	4.77	16.80	11.09	5.90
Net Income	-$193.88M	-$12.46M	$3.50B	$336.31M
7 Day Performance	-0.41%	-1.47%	-0.24%	0.09%
1 Month Performance	-25.97%	-7.56%	-2.97%	-5.67%
1 Year Performance	18.32%	48.75%	61.94%	18.79%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	3.7014 of 5 stars	$9.69 -4.2%	$23.82 +145.8%	+13.9%	$500.95M	$170.44M	N/A	370	Upcoming Earnings
RAPP Rapport Therapeutics	2.8207 of 5 stars	$41.93 +3.1%	$57.86 +38.0%	+185.4%	$2.01B	N/A	N/A	N/A	News Coverage Upcoming Earnings Analyst Forecast
ADMA ADMA Biologics	4.5623 of 5 stars	$8.60 +3.9%	$18.67 +117.2%	-54.8%	$1.99B	$509.86M	12.63	530	Trending News Upcoming Earnings
AUPH Aurinia Pharmaceuticals	3.7736 of 5 stars	$15.51 +1.0%	$17.25 +11.2%	+61.0%	$1.98B	$298.30M	7.11	300	News Coverage Positive News
PGEN Precigen	3.2053 of 5 stars	$5.57 +3.1%	$12.50 +124.6%	+266.7%	$1.98B	$9.68M	N/A	190	News Coverage Upcoming Earnings Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. RAPP, ADMA, AUPH, PGEN, and URGN

How does REGENXBIO compare to Rapport Therapeutics?

Summary

How does REGENXBIO compare to ADMA Biologics?

Summary

How does REGENXBIO compare to Aurinia Pharmaceuticals?

Summary

How does REGENXBIO compare to Precigen?

Summary

How does REGENXBIO compare to Urogen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. RAPP, ADMA, AUPH, PGEN, and URGN

How does REGENXBIO compare to Rapport Therapeutics?

Does the media favor RAPP or RGNX?

Which has better valuation & earnings, RAPP or RGNX?

Do analysts rate RAPP or RGNX?

Do institutionals & insiders believe in RAPP or RGNX?

Is RAPP or RGNX more profitable?

Which has more volatility and risk, RAPP or RGNX?

Summary

How does REGENXBIO compare to ADMA Biologics?

Does the media prefer RGNX or ADMA?

Which has better earnings and valuation, RGNX or ADMA?

Which has more volatility & risk, RGNX or ADMA?

Do institutionals and insiders hold more shares of RGNX or ADMA?

Is RGNX or ADMA more profitable?

Do analysts rate RGNX or ADMA?

Summary

How does REGENXBIO compare to Aurinia Pharmaceuticals?

Do analysts prefer AUPH or RGNX?

Which has more risk and volatility, AUPH or RGNX?

Is AUPH or RGNX more profitable?

Which has stronger valuation & earnings, AUPH or RGNX?

Does the media favor AUPH or RGNX?

Do insiders & institutionals have more ownership in AUPH or RGNX?

Summary

How does REGENXBIO compare to Precigen?

Is PGEN or RGNX more profitable?

Do insiders and institutionals have more ownership in PGEN or RGNX?

Do analysts prefer PGEN or RGNX?

Does the media favor PGEN or RGNX?

Which has more risk & volatility, PGEN or RGNX?

Which has better earnings and valuation, PGEN or RGNX?

Summary

How does REGENXBIO compare to Urogen Pharma?

Which has more volatility and risk, URGN or RGNX?

Does the media prefer URGN or RGNX?

Do analysts recommend URGN or RGNX?

Do institutionals & insiders believe in URGN or RGNX?

Is URGN or RGNX more profitable?

Which has better earnings and valuation, URGN or RGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools